Suppr超能文献

吸入性皮质类固醇在哮喘患者中的安全性和不良反应。

Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma.

机构信息

Department of Biomedical Sciences, Humanitas University, Milano, Italy; Personalized Medicine, Asthma and Allergy Clinic, Humanitas Research Hospital, Milano, Italy.

Personalized Medicine, Asthma and Allergy Clinic, Humanitas Research Hospital, Milano, Italy; Pediatrics, Allergy and Respiratory Disease, Mater Dei Hospital, Belo Horizonte, Brazil.

出版信息

J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):776-781. doi: 10.1016/j.jaip.2018.01.025. Epub 2018 Feb 3.

Abstract

Asthma is a common inflammatory airway disease for which the most commonly used controller medications are inhaled corticosteroids (ICS). Asthma control is difficult to achieve in individuals with severe asthma, which comprise 5% to 10% of individuals with asthma, even with high doses of ICS and other anti-inflammatory drugs. In this clinical context, the adverse effects of ICS (including hypothalamic-pituitary-adrenal axis suppression, reduction in growth velocity, osteoporosis, diabetes, and respiratory infections) become more probable and impacting on the quality of life of severe asthmatics. We here summarize the evidence of ICS-related adverse effects, particularly in patients with asthma. The possibility of using biologic agents earlier for severe asthma has the potential to prevent or reduce the occurrence of corticosteroid-related adverse effects, and also reduce corticosteroid-related costs.

摘要

哮喘是一种常见的气道炎症性疾病,最常用的控制药物是吸入性皮质类固醇(ICS)。即使使用高剂量的 ICS 和其他抗炎药物,严重哮喘患者(占哮喘患者的 5%至 10%)也难以控制哮喘。在这种临床情况下,ICS 的不良反应(包括下丘脑-垂体-肾上腺轴抑制、生长速度减慢、骨质疏松症、糖尿病和呼吸道感染)变得更加可能,并影响严重哮喘患者的生活质量。我们在这里总结了与 ICS 相关的不良反应的证据,特别是在哮喘患者中。尽早使用生物制剂治疗严重哮喘的可能性有可能预防或减少皮质类固醇相关不良反应的发生,并降低皮质类固醇相关成本。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验